NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

10th July 2015

UCB Comments on the Executable Model

UCB Comments on AG's Executable Model

Issue 1 Error in calculating MTX Response and LEF Response monitoring costs

Description of problem	Description of proposed correction	Result of amended model or expected impact on the result (if applicable)
Worksheet "**Costs**": there is an error in the formula in **Cell D89** which does not account for the right unit costs (c_mtx_response_mon): =SUMPRODUCT(D82:I82,D88:I88) = £1,700	Revise formula to: "=SUMPRODUCT(**D77:I77**,D88:I88) **=** £1340"	Expected minimal impact on the ICER, although not all AG analyses and scenarios were tested
Worksheet "**Costs**": there is an error in the formula in **Cell D91** which does not account for the right unit costs (c_lef_response_mon): =SUMPRODUCT(D84:I84,D90:I90) = £1,645	Revise formula to: =SUMPRODUCT(**D77:I77**,D90:I90) =£1590	Expected minimal impact on the ICER, although not all AG analyses and scenarios were tested

Issue 2 Error in calculating initial treatment cost for certolizumab pegol

Description of problem	Description of proposed correction	Result of amended model or expected impact on the result (if applicable)
Worksheet "**Costs**": in **cell G11** (c_r_CTZ), the formula to calculate the CTZ response cost is wrong. - Firstly, not all loading doses have been accounted for, the cost of 3 loading doses should be applied. Secondly, an additional month's worth of monitoring and administration costs have been included in the response period.	The formula in cell G11 should be replaced with: =(c_CTZ*6)+c_bio_pre_tx_mon+c_bio_response_mon-(7*S11) = £4514.65	Expected minimal impact on the ICER, although not all AG analyses and scenarios were tested